Pharvaris (NASDAQ:PHVS) Shares Gap Up - Still a Buy?

Pharvaris (NASDAQ:PHVS - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $18.12, but opened at $19.39. Pharvaris shares last traded at $17.96, with a volume of 8,845 shares.

Analyst Ratings Changes

PHVS has been the topic of several recent analyst reports. Cantor Fitzgerald lowered their target price on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and issued a $27.00 price target on shares of Pharvaris in a report on Thursday, June 5th. Finally, Guggenheim began coverage on Pharvaris in a research note on Wednesday. They set a "buy" rating and a $32.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $36.20.

Pharvaris Stock Up 0.6%

The business has a fifty day moving average of $15.75 and a 200 day moving average of $17.00. The company has a market cap of $896.77 million, a P/E ratio of -6.13 and a beta of -2.86.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09). On average, sell-side analysts anticipate that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Trading of Pharvaris

Institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG lifted its holdings in Pharvaris by 55.1% in the first quarter. Deutsche Bank AG now owns 28,174 shares of the company's stock valued at $442,000 after acquiring an additional 10,006 shares during the period. TD Asset Management Inc lifted its stake in shares of Pharvaris by 41.5% in the 1st quarter. TD Asset Management Inc now owns 78,122 shares of the company's stock worth $1,227,000 after purchasing an additional 22,906 shares during the period. Palumbo Wealth Management LLC boosted its holdings in shares of Pharvaris by 38.0% in the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock worth $221,000 after buying an additional 3,881 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Pharvaris by 30.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock worth $1,222,000 after buying an additional 14,838 shares during the last quarter. Finally, Woodline Partners LP bought a new stake in Pharvaris during the fourth quarter valued at approximately $853,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.